Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post-authorization safety study.
Soulmaz Fazeli FarsaniKristy IglayLing ZhangChristian NiyonkuruLaurieann NessrallaCynthia J GirmanPublished in: Pharmacoepidemiology and drug safety (2024)
The results of this voluntary post-approval safety study provide additional evidence that the use of empagliflozin for the treatment of T2D is not associated with an increased risk of acute pancreatitis.
Keyphrases